english.prescrire.org > Spotlight > Archives : 2025 > Relugolix + estradiol + norethisterone acetate (Ryeqo°) in endometriosis

Spotlight: Archives

Every month, the subjects in Prescrire’s Spotlight.

2025 : 1 | 30

Relugolix + estradiol + norethisterone acetate (Ryeqo°) in endometriosis

 Marketing Authorisations  Endometriosis is a condition related to the presence of uterine mucosal tissue (endometrium) outside of the uterus. When paracetamol or a nonsteroidal anti-inflammatory drug are not sufficient to relieve endometriosis-related pain, a hormonal contraceptive or an intrauterine device (IUD) that delivers levonorgestrel are options. Relugolix, a GnRH antagonist that induces menopausal symptoms, combined with an oestrogen-progestogen combination intended to attenuate these symptoms, is already authorised for the treatment of uterine fibroid symptoms, a situation in which it has an unfavourable harm-benefit balance. It is now also authorised for the treatment of endometriosis symptoms. 
Full article available for download by subscribers

 ©Prescrire 1 September 2025

Source: "Relugolix + estradiol + norethisterone acetate (Ryeqo°) in endometriosis" Prescrire Int 2025; 34 (273): 205-206. Subscribers only.

Filet

Enjoy full access to Prescrire International, and support independent information

 
Share
Share on Facebook  
 
 
See also:

"Relugolix + estradiol
+ norethisterone (Ryeqo°)
in uterine fibroids.
A risky hormone cocktail"
Prescrire Int 2023;
32 (244): 5-8.
Subscribers only
 
"Painful endometriosis.
If not planning a pregnancy:
paracetamol and NSAID,
or a combined oral contraceptive,
or a levonorgestrel IUD"
Prescrire Int 2020;
29 (213): 75.
Subscribers only